STAT

STAT+: Amylyx endocrine drug succeeds in pivotal study

STAT+: Amylyx endocrine drug succeeds in pivotal studyWorldPing

In a Phase 3 trial of people with post-bariatric hypoglycemia, those taking the drug, avexitide, experienced a 55% reduction in the rate of serious low blood sugar events compared with…

This is a short WorldPing brief. The full report was published by STAT.

Read the full report at STAT